Q32 Bio Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Q32 is a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory diseases. The quarter includes the March 25 reverse merger with Homology Medicines; for accounting purposes, Legacy Q32 was the acquirer, so pre-merger operating results primarily reflect Legacy Q32. The combined company began Nasdaq trading as QTTB on March 26.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $0 | $2.9 million |
| Research and development expense | $9.8 million | $7.9 million |
| General and administrative expense | $5.0 million | $2.4 million |
| Operating loss | $14.8 million | $7.4 million |
| Net income (loss) | $1.0 million | $(6.8) million |
| Net cash used in operations | $14.6 million | $12.5 million |
- Q1 net income included a $15.9 million noncash gain from remeasurement of convertible notes before they converted into common shares in connection with the merger. It does not indicate operating profitability.
- Operating expenses exceeded revenue by $14.8 million; with no product sales, gross margin is not applicable. R&D rose mainly as bempikibart trials advanced; G&A increased with merger, severance and public-company costs.
- At March 31, cash and cash equivalents were $115.5 million and short-term investments were $19.8 million, totaling $135.3 million. Current assets were $138.0 million and current liabilities $33.0 million.
- Cash, cash equivalents and restricted cash increased $84.9 million during the quarter, principally reflecting $53.2 million of cash acquired in the merger, $42.0 million of pre-closing financing and $7.0 million of new borrowing, partly offset by operating cash use and transaction costs.
- Venture debt was $12.5 million principal ($3.1 million current and $9.4 million noncurrent). The $38.6 million convertible-note liability at year-end converted into shares during the merger; no convertible notes remained on the March 31 balance sheet.
Material changes, outlook and risks
- Merger and financing: The reverse recapitalization brought in Homology net assets, including $53.2 million cash and a 20% equity-method investment in OXB (US) LLC. Legacy Q32 investors held approximately 74.4% of the combined company immediately after closing. The company also completed a $42.0 million pre-closing equity financing.
- Programs and milestones: Bempikibart Phase 2 enrollment in alopecia areata was completed in early Q2 2024; atopic dermatitis enrollment remained ongoing. Management expected topline data from both trials in Q4 2024. For ADX-097, management expected to initiate a Phase 2 renal basket program in H1 2024, with initial data by year-end 2024, and a Phase 2 AAV trial in H1 2025; topline data from both programs were anticipated in H2 2025.
- Cash runway: Management expected available cash, cash equivalents and short-term investments to fund operations through mid-2026, based on its current operating plan and assumptions. The company expects continued operating losses and negative operating cash flows and says additional capital will be needed to complete development and potentially commercialize its candidates.
- Contingent obligations: Following termination of the Horizon collaboration, Q32 retained bempikibart rights and the $55.0 million previously received, but may owe up to $75.1 million in regulatory and sales milestones. The merger also created a $5.1 million contingent value rights liability tied to proceeds from certain former Homology assets, including the OXB interest.
- Other key risks: Candidates remain in clinical development and may fail or be delayed; the company depends on third-party manufacturers and research organizations and on licensed intellectual property, including BMS rights for bempikibart. Management reported an unremediated material weakness in controls over complex accounting, citing insufficient personnel and review processes. No material legal proceedings were reported, and the company was in compliance with venture-debt covenants at quarter-end.
Important facts for investors to verify
- Whether bempikibart’s expected Q4 2024 data and ADX-097’s stated trial and data timelines were subsequently achieved.
- Whether the mid-2026 cash-runway estimate remains valid as trial spending, working-capital needs and other expenses evolve.
- The size, timing and likelihood of Horizon milestone payments and CVR payments, and the valuation assumptions behind the $5.1 million CVR liability.
- Progress in remediating the material weakness and the effect of merger-related accounting judgments on reported results.
- Future borrowing, dilution or partnership requirements, including any effects on existing shareholders and development plans.